NCT02370537 - A Study to Investigate How Common Pancreatic Exocrine Insufficiency (PEI) is in Patients With Type 2 Diabetes and Also to Investigate the Uptake of a Single Dose of EPANOVA® or OMACOR® in Patients With Different Degrees of PEI | Biotech Hunter

Enrollment

490

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

November 30, 2015

Study Completion Date

November 30, 2015

Conditions

Diabetes Mellitus, Type 2Exocrine Pancreatic Insufficiency

Interventions

DRUG

Epanova® (omega-3 carboxylic acids)

4 g (administered orally as 4 x 1 g capsules)

DRUG

Omacor® (omega-3-acid ethyl esters)

4 g (administered orally as 4 x 1 g capsules)

Trial Locations (22)

Research Site, Aarhus

Research Site, Frederiksberg

Research Site, København NV

Research Site, Balatonfüred

Research Site, Budapest

Research Site, Létavértes

Research Site, Daugavpils

Research Site, Jēkabpils

Research Site, Riga

Research Site, Bialystok

Research Site, Puławy

Research Site, Staszów

Research Site, Zamość

Research Site, Bardejov

Research Site, Bratislava

Research Site, Ľubochňa

Research Site, Gothenburg

Research Site, Linköping

Research Site, Lund

Research Site, Malmo

Research Site, Stockholm

Research Site, Uppsala